Another monotherapy trial is EMBER-2, an ongoing phase 1 study preoperative window studying the effects of imlunestrant on Stage I–III ER+ HER2− breast cancer in postmenopausal patients. The gene discussed is ESR1; the disease is breast carcinoma.